<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639585</url>
  </required_header>
  <id_info>
    <org_study_id>ESDAC</org_study_id>
    <nct_id>NCT02639585</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C</brief_title>
  <acronym>ESDAC</acronym>
  <official_title>Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We perform this study to identity efficacy and safety of Daclatasvir and Asunaprevir in real
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Responase</measure>
    <time_frame>week 12 (after treatment)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daclinza and Sunvepra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclinza and Sunvepra</intervention_name>
    <description>direct acting antiviral agent against to hepatitis C virus</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to provide written informed consent

          2. Males and females, ≥ 18 years of age

          3. HCV Genotype 1b who previously failed treatment with peginterferon alfa and ribavirin,
             classified as previous null or partial responders based on previous therapy, OR
             intolerant or ineligible to P/R due to neutropenia, anemia, depression or
             thrombocytopenia with fibrosis/cirrhosis, OR treatment naive

          4. HCV RNA ≥ 10,000 IU/mL

          5. Subjects with compensated cirrhosis are permitted

          6. Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen
             (HBsAg)

          7. Negative urine or serum pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of test drug.
             Additionally, all fertile males with partners of childbearing age and all females with
             childbearing potential must use reliable contraception method during the study and for
             3 months after treatment completion.

        Exclusion Criteria:

          1. Inability or unwillingness to provide informed consent or abide by the requirements of
             the study

          2. Other than genotype 1 infection

          3. Prior treatment of HCV with HCV direct acting antiviral agents (DAA)

          4. Patient who has any history of major organ transplantation with an existing functional
             graft or Patient who has plan to receive organ transplant

          5. Diagnosed or suspected hepatocellular carcinoma or other malignancies

          6. Evidence of decompensated liver disease including, but not limited to, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy

          7. Evidence of a medical condition contributing to chronic liver disease other than HCV

          8. Uncontrolled diabetes or hypertension

          9. Women with ongoing pregnancy or who are breast feeding

         10. Evidence of alcohol and/or drug abuse

         11. Patient who has NS5A resistance associated variant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Lim, M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Mi Hong, M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Lim, M.S.</last_name>
    <phone>+82-10-4513-7063</phone>
    <email>ezmagic@pusan.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won Lim, M.S.</last_name>
      <phone>+82-51-240-7869</phone>
      <email>ezmagic@pusan.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Mi Hong, M.S.</last_name>
      <phone>82-55-360-1570</phone>
      <email>00gurum@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.</citation>
    <PMID>24795200</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.</citation>
    <PMID>24720679</PMID>
  </reference>
  <reference>
    <citation>Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014 Nov 1;384(9954):1597-605. doi: 10.1016/S0140-6736(14)61059-X. Epub 2014 Jul 28. Erratum in: Lancet. 2014 Nov 1;384(9954):1576.</citation>
    <PMID>25078304</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>December 24, 2015</last_update_submitted>
  <last_update_submitted_qc>December 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Hospital</investigator_affiliation>
    <investigator_full_name>Won Lim</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>daclatasvir</keyword>
  <keyword>asunaprevir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

